The interleukin 1 inhibitor rilonacept in treatment of chronic gouty arthritis: results of a placebo-controlled, monosequence crossover, non-randomised, single-blind pilot study

BACKGROUND: Recent studies suggest that blockade of the NLRP3 (cryopyrin) inflammasome interleukin 1β (IL1β) pathway may offer a new treatment strategy for gout. OBJECTIVE: To explore the potential utility of rilonacept (IL1 Trap) in patients with chronic active gouty arthritis in a proof-of-concept...

Descripción completa

Detalles Bibliográficos
Autores principales: Terkeltaub, R, Sundy, J S, Schumacher, H R, Murphy, F, Bookbinder, S, Biedermann, S, Wu, R, Mellis, S, Radin, A
Formato: Texto
Lenguaje:English
Publicado: BMJ Group 2009
Materias:
Clinical and Epidemiological Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2732898/
https://www.ncbi.nlm.nih.gov/pubmed/19635719
http://dx.doi.org/10.1136/ard.2009.108936

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2732898/
https://www.ncbi.nlm.nih.gov/pubmed/19635719
http://dx.doi.org/10.1136/ard.2009.108936

Ejemplares similares